Table 1 Characteristics of all 402 patients in relationships with presence of cardiovascular diseases (CVDs).
Evaluated factors | All 402 patients N (%) | Patients with cardiovascular diseases N = 141 (%) | Patients without cardiovascular diseases N = 261 (%) | p value | |
|---|---|---|---|---|---|
Clasical CV risk factors | Diabetes | 20 (5.0) | 18 (12.8) | 2 (0.8) | < 0.0001 |
Obesity (BMI ≥ 30 kg/m2) | 83 (20.6) | 42 (29.8) | 41 (15.7) | 0.0009 | |
Older age (≥ 60y) | 185 (46) | 91 (64.5) | 94 (36) | < 0.000001 | |
Hypothyroidism | 17 (4.2) | 11 (7.8) | 6 (2.3) | 0.009 | |
Histopatological diagnosis | ER or PR positive | 331 (82.3) | 116 (82.3) | 215 (82.4) | 0.98 |
HER2 positive | 77 (19.2) | 32 (22.7) | 45 (17.2) | 0.18 | |
Triple negative | 48 (11.9) | 13 (9.2) | 35 (13.4) | 0.22 | |
Site of metastases | Pericardium / myocardium | 4 (1) | 2 (1.4) | 2 (0.8) | 0.92 |
Lung | 135 (33.6) | 56 (39.7) | 79 (30.3) | 0.056 | |
Pleura | 38 (9.5) | 16 (11.3) | 22 (8.4) | 0.34 | |
Liver | 179 (44.5) | 59 (41.8) | 120 (46) | 0.43 | |
Bone | 185 (46) | 63 (44.7) | 122 (46.7) | 0.69 | |
Nodules | 98 (24.4) | 39 (27.7) | 59 (22.6) | 0.26 | |
Soft tissue or skin | 45 (11.2) | 21 (14.9) | 24 (9.2) | 0.08 | |
Central nervous system | 36 (9) | 11 (7.8) | 25 (9.6) | 0.55 | |
Peritoneal metastases | 17 (4.2) | 5 (3.5) | 12 (4.6) | 0.81 | |
Ovary / uterus | 12 (3) | 5 (3.5) | 7 (2.7) | 0.86 | |
Local progression | 33 (8.2) | 7 (5.0) | 26 (10) | 0.08 | |
Previous adjuvant anticancer therapy | Radiotherapy: left-sided | 101 (25.1) | 32 (22.7) | 69 (26.4) | 0.41 |
Radiotherapy: right-sided | 126 (31.3) | 45 (31.9) | 81 (31) | 0.86 | |
Doxorubicin in adjuvant setting | 166 (41.3) | 53 (37.6) | 113 (43.3) | 0.27 | |
Taxanes in adjuvant setting | 74 (18.4) | 33 (23.4) | 41 (15.8) | 0.057 | |
Anti-HER2 in adjuvant setting | 19 (4.7) | 10 (7.1) | 9 (3.4) | 0.1 | |
Endocrine therapy in adjuvant setting | 64 (15.9) | 27 (19.1) | 37 (14.2) | 0.19 | |
Previous neoadjuvant anticancer therapy | No neoadjuvant | 305 (75.9) | 113 (80.1) | 192 (73.6) | 0.14 |
Doxorubicin in neoadjuvant setting | 96 (23.9) | 28 (19.9) | 68 (26.1) | 0.16 | |
Taxanes in neoadjuvant setting | 68 (16.9) | 17 (12.1) | 51 (19.5) | 0.056 | |
Doxorubicin and Taxanes in neoadjuvant setting | 67 (16.7) | 17 (12.1) | 50 (19.2) | 0.068 | |
Previous palliative anticancer therapy | Doxorubicin in palliative setting | 46 (11.4) | 15 (10.6) | 31 (11.9) | 0.71 |
Taxanes in palliative setting | 97 (24.1) | 31 (22) | 66 (25.3) | 0.46 | |
Anti-HER2 in palliative setting | 33 (8.2) | 13 (9.2) | 20 (7.7) | 0.59 | |
Endocrine therapy in palliative setting | 74 (18.4) | 29 (20.6) | 45 (17.2) | 0.41 | |
Previous treatment with conventional doxorubicin | Conventional doxorubicin dose ≥ 250 mg/m2 | 170 (42.3) | 51 (36.2) | 119 (45.6) | 0.068 |
Conventional doxorubicin dose ≥ 400 mg/m2 | 26 (6.5) | 6 (4.3) | 20 (7.7) | 0.18 | |
Taxane-naive | 190 (47.3) | 70 (49.6) | 120 (46) | 0.48 | |
Anthracycline—naive | 119 (29.6) | 51 (36.2) | 68 (26.1) | 0.03 | |
Characteristics of therapy with liposomal doxorubicin | First line in palliative setting | 234 (58.2) | 82 (58.2) | 152 (58.2) | 0.99 |
Cumulative dose > 300 mg/m2 | 158 (39.3) | 53 (37.6) | 105 (40.2) | 0.6 | |
Monotherapy | 82 (20.4) | 28 (19.9) | 54 (20.7) | 0.84 | |
Treatment time > 3.5 months | 202 (50.2) | 67 (47.5) | 135 (51.7) | 0.42 | |
Treatment time ≤ 2 months | 95 (23.6) | 39 (27.7) | 56 (21.5) | 0.16 | |
Cardiovascular events as end of treatment | 14 (3.5) | 8 (5.7) | 6 (2.3) | 0.078 | |
Heart failure as end of treatment | 13 (3.2) | 8 (5.7) | 5 (1.9) | 0.08 | |
Hematological toxicity as end of treatment | 20 (5) | 6 (4.3) | 14 (5.4) | 0.63 | |
Other toxicity as end of treatment | 12 (3) | 8 (5.7) | 4 (1.5) | 0.04 | |
PFS > 5 months | 196 (48.8) | 64 (45.4) | 132 (50.6) | 0.32 | |
Subsequent anticancer therapy | Cytostatics | 189 (47.1) | 68 (48.2) | 121 (46.4) | 0.72 |
Taxanes | 93 (23.1) | 27 (19.1) | 66 (25.3) | 0.18 | |
Endocrine therapy | 129 (32.1) | 47 (33.3) | 82 (31.4) | 0.69 | |
